Maeda, Chihiro et al. published their research in Angewandte Chemie, International Edition in 2020 |CAS: 14602-86-9

The Article related to bodipy azahelicene boron preparation benzothiazole benzoxazole derivative resolution, cd fluorescence cotton effect azahelicene benzothiazole benzoxazole bodipy, crystal structure bodipy azahelicene boron benzothiazole benzoxazole complex and other aspects.Related Products of 14602-86-9

On May 4, 2020, Maeda, Chihiro; Nagahata, Keiji; Shirakawa, Takuma; Ema, Tadashi published an article.Related Products of 14602-86-9 The title of the article was Azahelicene-Fused BODIPY Analogues Showing Circularly Polarized Luminescence. And the article contained the following:

Helical carbazole-based BODIPY analogs I (X = O, S; Y = F or YY = 1,1′-binaphthalene-2,2′-diolato; R = H, RR = benzo) were readily synthesized via aza[7]helicenes. The structures of azahelicene-incorporated BF2 dyes were elucidated by x-ray diffraction anal. DFT calculations revealed that the π-conjugated system expanded from the helicene moiety to the BODIPY framework. The azahelicene-fused boron complexes showed the Cotton effects and the circularly polarized luminescence (CPL) in the visible region. Furthermore, an axially chiral binaphthyl group was attached to the helically chiral dyes, which enhanced the chiroptical properties. The experimental process involved the reaction of (1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl carbonochloridate(cas: 14602-86-9).Related Products of 14602-86-9

The Article related to bodipy azahelicene boron preparation benzothiazole benzoxazole derivative resolution, cd fluorescence cotton effect azahelicene benzothiazole benzoxazole bodipy, crystal structure bodipy azahelicene boron benzothiazole benzoxazole complex and other aspects.Related Products of 14602-86-9

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

Cha, Eunju et al. published their research in Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences in 2016 |CAS: 14602-86-9

The Article related to hydroxycarboxylic acid enantiomer resolution derivation achiral gc, amide structure chiral hydroxy acid menthoxycarbonylated diastereomeric derivative gc, (−)-menthoxycarbonylated tert-butylamides, 2-hydroxy acids, enantiomeric separation and other aspects.SDS of cas: 14602-86-9

On February 15, 2016, Cha, Eunju; Kim, Sohee; Lee, Kang Mi; Kim, Ho Jun; Kim, Ki Hun; Kwon, Oh-Seung; Park, Ki Duk; Lee, Jaeick published an article.SDS of cas: 14602-86-9 The title of the article was Relationship between chromatographic resolution and amide structure of chiral 2-hydroxy acids as O-(-)-menthoxycarbonylated diastereomeric derivatives for enantiomeric separation on achiral gas chromatography. And the article contained the following:

The relation between chromatog. resolution and amide structure of chiral 2-hydroxy acids as O-(-)-menthoxycarbonylated diastereomeric derivatives on achiral gas chromatog. was studied to elucidate the best diastereomeric conformation for enantiomeric separation of chiral 2-hydroxy acids. Thirteen chiral 2-hydroxy acids were converted into nine different diastereomeric O-(-)-menthoxycarbonylated amide derivatives using the primary, secondary and cyclic amines to achieve complete enantiomeric separation through an achiral column. Each enantiomeric pair of 2-hydroxy acids as O-(-)-menthoxycarbonylated tert-butylamide derivatives was resolved on both the DB-5 and DB-17 columns with resolution factors ranging from 1.7 to 4.8 and 1.7 to 3.4, resp. The structure of the amide moiety is shown to significantly affect chromatog. resolution O-(-)-menthoxycarbonylated tert-butylamide derivatives are the best diastereomeric conformations for enantiomeric separation of 2-hydroxy acids. When comparing with the authors’ previous O-trifluoroacetylated(-)-menthyl ester derivatization method, the present results suggested that size differences between groups attached to the chiral center and conformational rigidity can have stronger effects on resolution than the distance between chiral centers. The elution of R- and S-stereoisomers was affected by the class of amine; i.e., primary, secondary, or cyclic, regardless of the substituents on the amine group, the structure of the 2-hydroxy acid, and the polarity of the column. The experimental process involved the reaction of (1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl carbonochloridate(cas: 14602-86-9).SDS of cas: 14602-86-9

The Article related to hydroxycarboxylic acid enantiomer resolution derivation achiral gc, amide structure chiral hydroxy acid menthoxycarbonylated diastereomeric derivative gc, (−)-menthoxycarbonylated tert-butylamides, 2-hydroxy acids, enantiomeric separation and other aspects.SDS of cas: 14602-86-9

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

Rastegari, Arezoo et al. published their research in Molecular Diversity in 2022 |CAS: 89-77-0

The Article related to phenyl tetrahydroacridinyl aminoethyl isoxazole preparation cholinesterase bace1 inhibition neuroprotection, mol docking sar metal chelation, alzheimer’s disease, bace1, cholinesterase, isoxazole, metal chelating, morris water maze, tacrine and other aspects.Related Products of 89-77-0

On February 28, 2022, Rastegari, Arezoo; Safavi, Maliheh; Vafadarnejad, Fahimeh; Najafi, Zahra; Hariri, Roshanak; Bukhari, Syed Nasir Abbas; Iraji, Aida; Edraki, Najmeh; Firuzi, Omidreza; Saeedi, Mina; Mahdavi, Mohammad; Akbarzadeh, Tahmineh published an article.Related Products of 89-77-0 The title of the article was Synthesis and evaluation of novel arylisoxazoles linked to tacrine moiety: in vitro and in vivo biological activities against Alzheimer’s disease. And the article contained the following:

Focusing on the efficient cholinesterase inhibitory activity of tacrine, design and synthesis of arylisoxazole-tacrine analogs, I [R = H, 4-F, 4-O2N, etc.; X = H, Cl] was developed. In-vitro acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition assay confirmed high potency of the title compds I. Among them, compounds I [R = 3-MeO, X = Cl; R = 4-Cl, X = H] demonstrated high activity toward AChE and BChE with IC50 values of 0.050 and 0.039μM, resp. Both compounds I [R = 3-MeO, X = Cl; R = 4-Cl, X = H] showed very good self-induced Aβ aggregation and AChE-induced inhibitory activity (79.4 and 71.4% for compound I [R = 3-MeO, X = Cl] and 61.8 and 58.6% for compound I [R = 4-Cl, X = H], resp.). Also, I [R = 3-MeO, X = Cl] showed good anti-BACE1 activity with IC50 value of 1.65μM. The metal chelation test indicated the ability of compounds I [R = 3-MeO, X = Cl; R = 4-Cl, X = H] to chelate biometals (Zn2+, Cu2+, and Fe2+). However, they showed no significant neuroprotectivity against Aβ-induced damage in PC12 cells. Evaluation of in-vitro hepatotoxicity revealed comparable toxicity of compounds I [R = 3-MeO, X = Cl; R = 4-Cl, X = H] with tacrine. In-vivo studies by Morris water maze (MWM) task demonstrated that compound I [R = 3-MeO, X = Cl] significantly reversed scopolamine-induced memory deficit in rats. Finally, mol. docking studies of compounds I [R = 3-MeO, X = Cl; R = 4-Cl, X = H] confirmed establishment of desired interactions with the AChE, BChE, and BACE1 active sites. The experimental process involved the reaction of 2-Amino-4-chlorobenzoic acid(cas: 89-77-0).Related Products of 89-77-0

The Article related to phenyl tetrahydroacridinyl aminoethyl isoxazole preparation cholinesterase bace1 inhibition neuroprotection, mol docking sar metal chelation, alzheimer’s disease, bace1, cholinesterase, isoxazole, metal chelating, morris water maze, tacrine and other aspects.Related Products of 89-77-0

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

Bendre, Shreya et al. published their research in Molecules in 2020 |CAS: 98946-18-0

The Article related to renal brush border enzyme cleavable linker kidney uptake, cancer imaging and therapy, cleavable linkers, kidney uptake, neutral endopeptidase (nep), prostate-specific membrane antigen (psma), radiopharmaceuticals, renal brush border enzymes and other aspects.Related Products of 98946-18-0

Bendre, Shreya; Zhang, Zhengxing; Kuo, Hsiou-Ting; Rousseau, Julie; Zhang, Chengcheng; Merkens, Helen; Roxin, Aron; Benard, Francois; Lin, Kuo-Shyan published an article in 2020, the title of the article was Evaluation of Met-Val-Lys as a renal brush border enzyme-cleavable linker to reduce kidney uptake of 68Ga-labeled DOTA-conjugated peptides and peptidomimetics.Related Products of 98946-18-0 And the article contains the following content:

High kidney uptake is a common feature of peptide-based radiopharmaceuticals, leading to reduced detection sensitivity for lesions adjacent to kidneys and lower maximum tolerated therapeutic dose. In this study, we evaluated if the Met-Val-Lys (MVK) linker could be used to lower kidney uptake of 68Ga-labeled DOTA-conjugated peptides and peptidomimetics. A model compound, [68Ga]Ga-DOTA-AmBz-MVK(Ac)-OH (AmBz: aminomethylbenzoyl), and its derivative, [68Ga]Ga-DOTA-AmBz-MVK(HTK01166)-OH, coupled with the PSMA (prostate-specific membrane antigen)-targeting motif of the previously reported HTK01166 were synthesized and evaluated to determine if they could be recognized and cleaved by the renal brush border enzymes. Addnl., positron emission tomog. (PET) imaging, ex vivo biodistribution and in vivo stability studies were conducted in mice to evaluate their pharmacokinetics. [68Ga]Ga-DOTA-AmBz-MVK(Ac)-OH was effectively cleaved specifically by neutral endopeptidase (NEP) of renal brush border enzymes at the Met-Val amide bond, and the radio-metabolite [68Ga]Ga-DOTA-AmBz-Met-OH was rapidly excreted via the renal pathway with minimal kidney retention. [68Ga]Ga-DOTA-AmBz-MVK(HTK01166)-OH retained its PSMA-targeting capability and was also cleaved by NEP, although less effectively when compared to [68Ga]Ga-DOTA-AmBz-MVK(Ac)-OH. The kidney uptake of [68Ga]Ga-DOTA-AmBz-MVK(HTK01166)-OH was 30% less compared to that of [68Ga]Ga-HTK01166. Our data demonstrated that derivatives of [68Ga]Ga-DOTA-AmBz-MVK-OH can be cleaved specifically by NEP, and therefore, MVK can be a promising cleavable linker for use to reduce kidney uptake of radiolabeled DOTA-conjugated peptides and peptidomimetics. The experimental process involved the reaction of tert-Butyl trichloroacetimidate(cas: 98946-18-0).Related Products of 98946-18-0

The Article related to renal brush border enzyme cleavable linker kidney uptake, cancer imaging and therapy, cleavable linkers, kidney uptake, neutral endopeptidase (nep), prostate-specific membrane antigen (psma), radiopharmaceuticals, renal brush border enzymes and other aspects.Related Products of 98946-18-0

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

Ghorbani, Mahdi et al. published their research in Environmental Science and Pollution Research in 2018 |CAS: 99-60-5

The Article related to ethylene diamine graphene oxide adsorption lead cadmium wastewater treatment, adsorption, batteries wastewater samples, electroplating wastewater samples, magnetic ethylene diamine-functionalized graphene oxide, removal of lead and cadmium ions and other aspects.HPLC of Formula: 99-60-5

On February 28, 2018, Ghorbani, Mahdi; Shams, Alireza; Seyedin, Orkideh; Afshar Lahoori, Nahid published an article.HPLC of Formula: 99-60-5 The title of the article was Magnetic ethylene diamine-functionalized graphene oxide as novel sorbent for removal of lead and cadmium ions from wastewater samples. And the article contained the following:

In this paper, magnetic ethylene diamine-functionalized graphene oxide (MDFGO) as a novel sorbent was synthesized and applied for removal of Pb(II) and Cd(II) from real wastewater samples. The morphol. and mol. structure of MDFGO were studied by different anal. methods. The effective parameters in adsorption efficiency of Pb(II) and Cd(II) were studied and optimized using exptl. design. Under the optimal condition, the effective parameters including pH, sorbent dosage, shaking rate, and adsorption time were 6.2, 33.0 mg, 500 rpm, and 11 min, resp. Mechanism of adsorption kinetic was investigated using the Lagergren pseudo-first-order, pseudo-second-order, and intraparticle diffusion models. It was found that adsorption of lead and cadmium ions in the MDFGO sorbent followed from pseudo-first-order and pseudo-second-order models, resp. Thermodn. parameters (ΔG°, ΔH°, and ΔS°) for the lead and cadmium ions uptake onto the MDFGO sorbent were calculated and indicated that the adsorption processes were spontaneous and endothermic in nature for both cations. In order to investigate the isotherm model for adsorption of Pb(II) and Cd(II), the exptl. data were studied using the Langmuir, Freundlich, and Harkins-Jura isotherm models. The results fitted well with Freundlich model for both metal ions. The new sorbent (MDFGO) was applied to remove Pb(II) and Cd(II) from battery wastewater and electroplating wastewater. The removal percentage of Pb(II) and Cd(II) were 99.6±0.5 and 99.4±0.6, resp., and demonstrated that the new sorbent was very suitable for removal of lead and cadmium ion from the real wastewater samples. The experimental process involved the reaction of 2-Chloro-4-nitrobenzoic acid(cas: 99-60-5).HPLC of Formula: 99-60-5

The Article related to ethylene diamine graphene oxide adsorption lead cadmium wastewater treatment, adsorption, batteries wastewater samples, electroplating wastewater samples, magnetic ethylene diamine-functionalized graphene oxide, removal of lead and cadmium ions and other aspects.HPLC of Formula: 99-60-5

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

Wei, Hao-Zhao et al. published their research in Organic & Biomolecular Chemistry in 2020 |CAS: 89-77-0

The Article related to cyclopenta naphthalene indole preparation, propargylic alc alkylidenecyclopropane indole cyclization lewis acid catalyst, naphthalene cyclopenta pyrrole preparation, pyrrole propargylic alc alkylidenecyclopropane cyclization lewis acid catalyst and other aspects.Product Details of 89-77-0

Wei, Hao-Zhao; Yu, Liu-Zhu; Shi, Min published an article in 2020, the title of the article was Lewis or Bronsted acid-catalysed reaction of propargylic alcohol-tethered alkylidenecyclopropanes with indoles and pyrroles for the preparation of polycyclic compounds tethered with indole or pyrrole motif.Product Details of 89-77-0 And the article contains the following content:

A facile synthetic method to access cyclopenta[b]naphthalene derivatives I (R1 = H, 3-Me, 5-Me, 4-CF3, 5-OMe, 4-MeO, 4-Cl; R2 = Ph, 4-MeOC6H4, 3-thienyl; R3 = H, Me, OMe, Cl, F; R4 = H, Me, OMe, Cl; R5 = N-methylpyrrol-2-yl, indol-3-yl, N-phenylindol-3-yl, etc.) via the Lewis or Bronsted acid catalyzed cascade nucleophilic addition, electronic cyclization, ring-opening rearrangement of propargylic alc.-tethered alkylidenecyclopropanes II (R6 = H, 5-MeO, 5-Cl, 6-Me, etc.) with indole and pyrrole derivatives was developed. The reaction exhibited a broad substrate scope and good functional group tolerance under metal-free conditions, affording the desired products in moderate to good yields. The experimental process involved the reaction of 2-Amino-4-chlorobenzoic acid(cas: 89-77-0).Product Details of 89-77-0

The Article related to cyclopenta naphthalene indole preparation, propargylic alc alkylidenecyclopropane indole cyclization lewis acid catalyst, naphthalene cyclopenta pyrrole preparation, pyrrole propargylic alc alkylidenecyclopropane cyclization lewis acid catalyst and other aspects.Product Details of 89-77-0

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

MacLean, Mark A. et al. published their research in Bioorganic & Medicinal Chemistry Letters in 2016 |CAS: 452-75-5

The Article related to edaravone derivative preparation palladium catalyzed protein misfolding beta amyloid, alzheimers treatment edaravone derivative beta amyloid tau aggregation inhibitor, alzheimer’s disease, beta-amyloid, hydrazine, palladium-catalyzed aminations and other aspects.HPLC of Formula: 452-75-5

On January 1, 2016, MacLean, Mark A.; Diez-Cecilia, Elena; Lavery, Christopher B.; Reed, Mark A.; Wang, Yanfei; Weaver, Donald F.; Stradiotto, Mark published an article.HPLC of Formula: 452-75-5 The title of the article was Diversification of edaravone via palladium-catalyzed hydrazine cross-coupling: Applications against protein misfolding and oligomerization of beta-amyloid. And the article contained the following:

N-Aryl derivatives of edaravone were identified as potentially effective small mol. inhibitors of tau and beta-amyloid aggregation in the context of developing disease-modifying therapeutics for Alzheimer’s disease (AD). Palladium-catalyzed hydrazine monoarylation protocols were then employed as an expedient means of preparing a focused library of 21 edaravone derivatives featuring varied N-aryl substitution, thereby enabling structure-activity relationship (SAR) studies. On the basis of data obtained from two functional biochem. assays examining the effect of edaravone derivatives on both fibril and oligomer formation, it was determined that derivatives featuring an N-biaryl motif were four-fold more potent than edaravone. The experimental process involved the reaction of 4-Chloro-2-fluorotoluene(cas: 452-75-5).HPLC of Formula: 452-75-5

The Article related to edaravone derivative preparation palladium catalyzed protein misfolding beta amyloid, alzheimers treatment edaravone derivative beta amyloid tau aggregation inhibitor, alzheimer’s disease, beta-amyloid, hydrazine, palladium-catalyzed aminations and other aspects.HPLC of Formula: 452-75-5

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

Myers, Jason K. et al. published their patent in 2002 |CAS: 400715-69-7

The Article related to quinuclidine heteroaryl preparation neurol disorder treatment, alzheimer disease treatment quinuclidine heteroaryl preparation, dementia treatment quinuclidine heteroaryl preparation, nicotinic receptor binding quinuclidine heteroaryl preparation and other aspects.Computed Properties of 400715-69-7

On February 28, 2002, Myers, Jason K.; Rogers, Bruce N.; Groppi, Vincent E., Jr.; Piotrowski, David W.; Bodnar, Alice L.; Jacobsen, Eric Jon; Corbett, Jeffrey W. published a patent.Computed Properties of 400715-69-7 The title of the patent was Preparation of N-quinuclidinyl-heteroaryl amides for pharmaceutical use in the treatment of neurological disorders. And the patent contained the following:

N-quinuclidinyl-heteroaryl amides, such as I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use in the treatment of neurol. disorders, such as attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down’s syndrome, dementia associated with Lewy Bodies, Huntington’s disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson’s disease, tardive dyskinesia, Pick’s disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette’s Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, the hydrochloride salt of quinuclidine carboxamide II was prepared in 57% yield by an amidation reaction of (3R)-3-aminoquinuclidine hydrochloride and 5-phenylthiophene-2-carboxylic acid using di-Ph chlorophosphate and Et3N in CH2Cl2 and DMF/H2O (5:1). The prepared quinuclidinyl amides were tested for nicotinic acetylcholine receptor binding activities. The experimental process involved the reaction of Ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate(cas: 400715-69-7).Computed Properties of 400715-69-7

The Article related to quinuclidine heteroaryl preparation neurol disorder treatment, alzheimer disease treatment quinuclidine heteroaryl preparation, dementia treatment quinuclidine heteroaryl preparation, nicotinic receptor binding quinuclidine heteroaryl preparation and other aspects.Computed Properties of 400715-69-7

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

Meyers, Jason K. et al. published their patent in 2002 |CAS: 400715-69-7

The Article related to quinuclidine heteroaryl preparation neurol disorder treatment, alzheimer disease treatment quinuclidine heteroaryl preparation, dementia treatment quinuclidine heteroaryl preparation, nicotinic receptor binding quinuclidine heteroaryl preparation and other aspects.Product Details of 400715-69-7

On February 28, 2002, Meyers, Jason K.; Rogers, Bruce N.; Groppi, Vincent E., Jr.; Piotrowski, David W.; Bodnar, Alice L.; Jacobsen, Eric Jon; Corbett, Jeffrey W. published a patent.Product Details of 400715-69-7 The title of the patent was Preparation of N-quinuclidinyl-heteroaryl amides for pharmaceutical use in the treatment of neurological disorders. And the patent contained the following:

N-quinuclidinyl-heteroaryl amides, such as I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use in the treatment of neurol. disorders, such as cognitive and attention deficit symptoms of Alzheimer’s, neurodegeneration associated with diseases such as Alzheimer’s disease, pre-senile dementia (mild cognitive impairment), or senile dementia. Thus, the hydrochloride salt of quinuclidine carboxamide II was prepared in 57% yield by an amidation reaction of (3R)-3-aminoquinuclidine hydrochloride and 5-phenylthiophene-2-carboxylic acid using di-Ph chlorophosphate and Et3N in CH2Cl2 and DMF/H2O (5:1). The prepared quinuclidinyl amides were tested for nicotinic acetylcholine receptor binding activities. The experimental process involved the reaction of Ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate(cas: 400715-69-7).Product Details of 400715-69-7

The Article related to quinuclidine heteroaryl preparation neurol disorder treatment, alzheimer disease treatment quinuclidine heteroaryl preparation, dementia treatment quinuclidine heteroaryl preparation, nicotinic receptor binding quinuclidine heteroaryl preparation and other aspects.Product Details of 400715-69-7

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

Fukuoka, Shinsuke et al. published their patent in 1987 |CAS: 452-75-5

The Article related to fluoroarom carboxylate aryl ester preparation, fluorobenzoate phenyl ester preparation, pharmaceutical agrochem intermediate aryl fluoroarom carboxylate, heat resistant polymer intermediate fluoroarycarboxylate ester, carbonylation fluoroaryl halide and other aspects.Reference of 4-Chloro-2-fluorotoluene

On September 2, 1987, Fukuoka, Shinsuke published a patent.Reference of 4-Chloro-2-fluorotoluene The title of the patent was A process for preparation of aryl fluorinated aromatic carboxylates by carbonylation of fluorinated aryl halides in the presence of phenols. And the patent contained the following:

The title compounds, useful as intermediates for heat-resistant polymers, agrochems., and pharmaceuticals, are prepared A mixture of p-IC6H4F 22.2, PhOH 11.3, Bu3N 22.2, and Ni(acac)2 0.77 g was autoclaved under CO at 50 kg/cm2 and 200-220° for 2 h to give 95% p-FC6H4CO2Ph. The experimental process involved the reaction of 4-Chloro-2-fluorotoluene(cas: 452-75-5).Reference of 4-Chloro-2-fluorotoluene

The Article related to fluoroarom carboxylate aryl ester preparation, fluorobenzoate phenyl ester preparation, pharmaceutical agrochem intermediate aryl fluoroarom carboxylate, heat resistant polymer intermediate fluoroarycarboxylate ester, carbonylation fluoroaryl halide and other aspects.Reference of 4-Chloro-2-fluorotoluene

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics